2020 ASCO Virtual Direct™ Highlights
Avatar

2020 ASCO Update on IO in mNSCLC: Should We Still Consider Chemotherapy Alone as a SoC? Is There a Benefit to Ipi/Nivo Combos Over Chemo + PD-1 Approach?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Ryan Gentzler
By 2020 ASCO Virtual Direct™ Highlights FEATURING Ryan Gentzler
348 views
August 4, 2020
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
18:47
Total Health

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Feat. W. Iams
35:40
Balazs Halmos

Year in Review: Lung Cancer

17:20
Total Health

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Feat. J. Porter
13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Feat. E. Rodriguez
08:49
David Carbone

The Use of IO Doublet in PD-L1-Negative NSCLC

07:31
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "KEYNOTE-671 Trial Key Learnings & Cli…

Feat. J. West
14:49
Vivek Subbiah

Year in Review: Precision Medicine

16:12
Total Health

2024 Updates on the Fast-Changing NSCLC Landscape

Feat. R. Osarogiagbon
23:32
2023 West Oncology Conference

2023 Updates on Neoadjuvant and Adjuvant NSCLC

Feat. M. Johnson
11:50
GRACE

The CheckMate 816 Trial: The Success of Neoadjuvant NSCLC Therapies

Feat. J. Rotow
17:34
ecancer

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

Feat. L. Raez
08:30
Insights from 2023 ESMO Annual Meeting

PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EG…

Feat. N. Girard
54:26
Yale Cancer Center

Year in Review: Progress in NSCLC Treatment

Feat. R. Herbst
20:27
Yale Cancer Center

Progress in the Treatment of NSCLC

Feat. R. Herbst
23:36
CHEST 2022 Coverage

Immune Checkpoint Inhibitor Pneumonitis in Lung Cancer

Feat. J. Possick
26:42
Total Health

ADAURA & KEYNOTE-671 Trials: Early Stage NSCLC Updates - 2023 AS…

Feat. J. Bauman
17:57
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Expert Discussion on New Treatment Options…

Feat. D. Carbone, B. Stiles
08:05
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ARC-7: Randomized Phase 2 Study of Domvan…

Feat. M. Johnson
08:15
ecancer

ESMO 2023 Summary: "Highlights From Recent NSCLC Trials"

Feat. B. Gyawali
23:29
2023 Evolution Conference

IO and Targeted Treatment for mNSCLC

Feat. M. Mooradian